CoChat

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 23 of the 33 sources its claims cite were checked for support.

Abstract

Protocol for a randomized trial testing early combined UDCA and OCA in high-risk PBC.

Overview

CoChat Summary

TL;DR

OPERA is a multicentre, randomised, double-blind, placebo-controlled trial testing obeticholic acid plus UDCA as first-line therapy in 106 adults within 6 months of PBC diagnosis who are at enhanced risk of non-response to UDCA. The primary efficacy outcome is normalisation of serum alkaline phosphatase and total bilirubin at 26 weeks, with an optional liver biopsy sub-study examining bile duct senescence.

Key findings

  • The trial plans to randomise 106 participants 1:1 to UDCA plus OCA (n=53) or UDCA plus matched placebo (n=53), with a 26-week treatment phase and a 26-week follow-up period; the primary outcome is the percentage showing normalisation of serum alkaline phosphatase and total bilirubin at 26 weeks (disease remission).
  • Sample size is powered at 90% using an augmented binary method; assumptions are a 20% control-arm normalisation rate at 6 months and a 45% experimental-arm normalisation rate, whereas a binary analysis would require 144 patients, and the augmented method reduces this to 48 per arm, increased by 10% to 53 per arm for dropout.
  • An optional liver biopsy sub-study (n=30) will take pre- and post-therapy biopsies for immunohistochemistry analysis of senescence markers; the trial will also validate a chemokine composite biomarker based on CCL20 and CXCL11, reported to have a positive predictive value of 94%, negative predictive value of 78%, and area under the receiver operator curve of 0.91 for identifying UDCA non-responders.
  • The protocol challenges the current step-up model by using the validated UDCA Response Score to identify high-risk patients at diagnosis and offering OCA from the outset; OCA/placebo is given at 5 mg once daily for 12 weeks, then titrated to 10 mg once daily until week 26 according to tolerability, with UDCA prescribed per NHS standard of care.

Methods

  • Design: multicentre, double-blind, superiority, randomised, placebo-controlled CTIMP in England, recruiting from 14 centres; participants are adults within 6 months of PBC diagnosis, non-cirrhotic, with less than 3 months of UDCA treatment at consent and enhanced risk of non-response based on URS, randomised 1:1 with stratification by consent to the biopsy sub-study.
  • Intervention and follow-up: OCA or matched placebo is taken orally at 5 mg once daily for 12 weeks, then titrated to 10 mg once daily from week 12 to week 26 according to tolerability; participants attend up to five in-person visits and one phone call, with clinical review, examination, vital signs, blood sampling, urine sampling, transient elastography, compliance checks, EQ-5D-5L, PBC-40, and Patient Health Questionnaire assessments.
  • Analysis: primary analysis is intention-to-treat and repeated in per-protocol; the augmented binary method fits a bivariate normal regression model to ALP and bilirubin values expressed as percentage of ULN, estimates the OR of normalisation between arms, and obtains a 95% CI and p value via the delta method and Wald test; missing primary outcome data with >5% loss to follow-up may prompt multiple imputation sensitivity analysis.

Limitations

  • Stated: the trial relies on a biochemical surrogate marker (blood liver biochemistry) as the primary endpoint and is not designed or powered to explore true clinical outcomes; it also explores only one advanced PBC therapy, OCA, and not alternatives such as elafibranor or seladelpar, which were licensed after the trial was designed and commenced.
  • Stated: placebo-controlled trials of long-term therapy in a chronic disease such as PBC are very challenging, especially when second-line therapies are available on a conditional approval basis following UDCA failure, and the use and regulatory acceptability of surrogate markers in PBC has been controversial.
  • Evident from the text: this is a protocol with no efficacy or safety results reported; the first patient was recruited in January 2024, and the manuscript is based on trial protocol V.6.0 dated 27 October 2025.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2025-113812

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Participant flow diagram. FBC, full blood count; OPERA, Optimising Primary thErapy in pRimAry; PBC, primary biliary cholangitis; POCBP, people of childbearing potential; U&Es, urea and electrolytes; UDCA, ursodeoxycholic acid; URS, UDCA Response Score; GGT, gamma-glutamyl transferase; EQ-5D-5L, EuroQoL 5 Dimensions 5 Levels.
Figure 1 Participant flow diagram. FBC, full blood count; OPERA, Optimising Primary thErapy in pRimAry; PBC, primary biliary cholangitis; POCBP, people of childbearing potential; U&Es, urea and electrolytes; UDCA, ursodeoxycholic acid; URS, UDCA Response Score; GGT, gamma-glutamyl transferase; EQ-5D-5L, EuroQoL 5 Dimensions 5 Levels.CC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 3 Not valid · 5 Not checked · 20 Own results and interpretations

22 more claims · 10 with their cited sources checked

Create a free account to see all 47 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 10
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 35 references

Metadata

Authors
Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., Banham, A., Hale, F., Christie, M., Barclay, S. T., Dyson, J., Smith, R., Aithal, G., Culver, E., Aspinall, R., Thorburn, D., Heneghan, M., Hancock, H. C., Trivedi, P., Mells, G., Wason, J., & Jones, D. E. J.
Affiliations
  • Newcastle University (GB)
  • PPIE, Newcastle upon tyne, UK
  • PBC Foundation (GB)
  • Glasgow Royal Infirmary (GB)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Queen's Medical Centre (GB)
  • Oxford University Hospitals NHS Trust (GB)
  • Portsmouth Hospitals NHS Trust (GB)
  • Department of Hepatology, Royal Free London NHS Trust, London, UK
  • King's College London (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • University of Cambridge (GB)
  • NIHR Newcastle Biomedical Research Centre (GB)
Corresponding author
Jones, David E J
Venue
BMJ Open
Publisher
BMJ
Published
2026-03
Volume
16
Issue
3
Pages
e113812
ISSN
2044-6055 (ISSN-L)
OpenAlex
W7135016756
Cited by
0
References
34
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Funders
Efficacy and Mechanism Evaluation Programme (NIHR131359)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
Keywords
primary biliary cirrhosis, obeticholic acid, ursodeoxycholic acid, combination therapy, first-line therapy, disease-modifying therapy, farnesoid X receptor agonist, biochemical remission
MeSH terms
Receptor, Farnesoid X-Activated, Chenodeoxycholic Acid, Cholagogues and Choleretics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid. https://app.cochat.ai/papers/10.1136/bmjopen-2025-113812
The paper
Dunn, S., Evans, L., Kennedy, C., Wafer, R., Moody, S., Wolstenhulme, F., Burton, E., Konkoth, A. B., Fisher, H., Chadwick, T., Banham, A., Hale, F., Christie, M., Barclay, S. T., Dyson, J., Smith, R., Aithal, G., Culver, E., Aspinall, R., . . . Jones, D. E. J. (2026). Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid. BMJ Open. https://doi.org/10.1136/bmjopen-2025-113812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.